NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

NovaGo Therapeutics AG has successfully completed a Series B financing round, raising CHF 24 million (approximately USD 30 million) to propel its lead program into a proof-of-concept study for patients with acute spinal cord injury. The financing, announced on September 2, 2026, was co-led by Neurimmune and Pureos Bioventures, with participation from both existing and new investors. Additionally, the round was bolstered by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation.

Founded in Switzerland, NovaGo Therapeutics is a clinical-stage biotechnology firm focused on developing anti-Nogo-A biologics aimed at promoting nerve regeneration and functional recovery in patients suffering from central nervous system injuries and diseases. The company's lead candidate, NG004, targets the Nogo-A protein, which is known to inhibit nerve fiber regeneration. This approach is particularly relevant in the context of spinal cord injuries, where there are currently no approved regenerative treatments that can restore lost neurological function.

The Series B financing will enable NovaGo to advance its clinical program, specifically a fully randomized, double-blind trial that will enroll 120 patients across clinical sites in Germany, Spain, and Switzerland. This study marks a critical step in assessing the efficacy of NG004 in promoting nerve outgrowth and functional recovery following spinal cord injury. The high unmet medical need in this area underscores the importance of NovaGo's work, as current treatment options for spinal cord injuries remain limited.

Neurimmune, a clinical-stage biopharmaceutical company, is known for its innovative antibody therapeutics targeting central nervous system diseases. The company has made significant strides in developing therapies for conditions such as Alzheimer’s disease and amyotrophic lateral sclerosis. Pureos Bioventures, a venture fund focused on private innovative drug development, also sees potential in NovaGo’s approach, expressing optimism about the Phase 1 results and the prospects for a new regenerative treatment option for spinal cord injury patients.

The successful fundraising round reflects a growing interest in biotechnology, particularly in the realm of regenerative medicine. As the sector continues to evolve, companies like NovaGo Therapeutics are at the forefront of addressing critical healthcare challenges. With substantial backing from both venture capital and philanthropic sources, NovaGo is well-positioned to advance its clinical programs and contribute to the development of much-needed therapies for spinal cord injuries. The outcomes of the upcoming proof-of-concept study could have significant implications for the future of treatment options in this area, potentially paving the way for breakthroughs in regenerative medicine.